# Clinical Trial Compliance Analysis Report

**Generated:** 2026-01-05 12:01:24

## Document Information

- **Protocol:** diabetes_phase3.pdf
- **Requirements:** diabetes_requirements.txt

## Executive Summary

### Overall Compliance: 85.0% ðŸŸ¢ **HIGH COMPLIANCE**

| Metric | Count | Percentage |
|--------|-------|------------|
| **Total Requirements** | 10 | 100% |
| âœ… Followed | 7 | 70.0% |
| âš ï¸ Partial | 2 | 20.0% |
| âŒ Not Followed | 1 | 10.0% |
| âž– Not Applicable | 0 | 0.0% |

## Key Findings

âš ï¸ **1 requirement(s) not followed** - These require immediate attention.

âš ï¸ **2 requirement(s) partially met** - These may need clarification or modification.

---

## Detailed Requirements Analysis

### âŒ Requirements Not Followed

*Found 1 requirement(s) in this category*

#### 1. Study must include pediatric population aged 12-17

**Full Requirement:**
> Study must include pediatric population aged 12-17

**Confidence Score:** 90%

**Analysis:**
Protocol explicitly excludes participants under 18 years of age.

*Based on 1 relevant protocol section(s)*

---

### âš ï¸ Partially Met Requirements

*Found 1 requirement(s) in this category*

#### 1. Safety monitoring must include adverse event reporting within 24 hours

**Full Requirement:**
> Safety monitoring must include adverse event reporting within 24 hours

**Confidence Score:** 80%

**Analysis:**
Protocol includes AE reporting but specifies 48-hour timeline for serious events.

*Based on 2 relevant protocol section(s)*

---

### âœ… Fully Compliant Requirements

*Found 1 requirement(s) in this category*

#### 1. Primary endpoint must be HbA1c reduction from baseline

**Full Requirement:**
> Primary endpoint must be HbA1c reduction from baseline

**Confidence Score:** 95%

**Analysis:**
The protocol explicitly defines HbA1c reduction as the primary endpoint, measured at 12 and 24 weeks.

*Based on 3 relevant protocol section(s)*

---

## Recommendations

### Critical Actions Required

1. **Address 1 non-compliant requirement(s)**
   - Review protocol sections related to these requirements
   - Consider protocol amendments if necessary
   - Document justification if requirements cannot be met

### Recommended Actions

1. **Clarify 2 partially met requirement(s)**
   - Review specific gaps identified in the analysis
   - Enhance protocol documentation where needed
   - Seek stakeholder approval for partial compliance

### Overall Assessment

âœ… The protocol demonstrates strong compliance with the requirements.
Focus on addressing any remaining gaps to achieve full compliance.

---

## Analysis Metadata

- **Analysis Date:** 2026-01-05 12:01:24
- **Protocol Document:** `data/protocols/diabetes_phase3.pdf`
- **Requirements Document:** `data/requirements/diabetes_requirements.txt`
- **Analysis Method:** LangChain-powered LLM analysis with vector retrieval
- **Requirements Analyzed:** 10

---

*Generated by Clinical Trial Protocol Matcher - LangChain + DeepSeek*
